The US Food and Drug Administration granted accelerated approval on Thursday 5 November to Rybrevant Faspro, a dual-targeted antibody combination made by Janssen Biotech. The drug is licensed for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed after platinum-based chemotherapy and immunotherapy.
The clearance is the first approval in ten years for that patient group and the first in the United States for a dual-targeted therapy in the disease. The product is amivantamab and hyaluronidase-lpuj, and it received Breakthrough Therapy designation for the indication before the decision. Janssen Biotech is part of Johnson & Johnson.
What the trial showed
The approval rests on a single-arm trial of 102 patients, all of them with recurrent or metastatic disease that had progressed after platinum chemotherapy and immunotherapy. The overall response rate was 42 per cent, or roughly two in five patients, and 56 per cent of responses lasted six months or longer. The FDA said that currently approved therapies are associated with response rates of around 20 per cent or less. Set beside that figure, the 42 per cent response rate is the substance of the case for the drug.
The trial did not compare the combination against an existing treatment. The 42 per cent figure is a single-arm result rather than the product of a head-to-head study, and the regulator’s assessment turned on the size and the durability of the responses observed. The comparison is therefore against a benchmark from earlier therapies rather than against a control group inside the same study.
Who the approval covers
The indication is limited to adults with recurrent or metastatic disease after platinum chemotherapy and immunotherapy. It does not cover HPV-associated oropharyngeal cancer, an exclusion that narrows the group the label reaches. The label does not extend to earlier lines of treatment or to newly diagnosed disease. Warnings and precautions include hypersensitivity and administration-related reactions, interstitial lung disease, dermatologic reactions, ocular toxicity and fetal harm.
Approval was granted under the accelerated pathway, which lets a drug reach patient before the survival data that a full approval requires, on condition that confirmatory trials follow. The basis was response rate and durability rather than survival from a randomised trial, and the clearance carries an obligation to supply those trials. Continued authorisation depends on those trials verifying the benefit seen in the single-arm study.
Confirmatory data required
Angelo De Claro, director of the FDA’s Oncology Center of Excellence, described the approval as a meaningful advance for a disease with historically limited options. The regulator’s framing is narrower than a cure: a new option for advanced disease after two standard lines of treatment have failed. That distinction matters for patients weighing the treatment against its warnings, because the evidence rests on response rather than on longer survival.
The evidence base is small and comes from one study of just over a hundred patients. The burden of proof therefore sits with the confirmatory work rather than with the clearance itself.
For patients and their clinicians, the practical change is that a dual-targeted option now exists for a narrowly defined group, with a response rate roughly double that of existing therapies. The safety profile requires monitoring for administration reactions, lung inflammation and eye toxicity. Whether it extends survival is not established in the data submitted with the approval, and that is the question the confirmatory trials are meant to answer.
